Furthermore, inhibiting the PCSK9 protein in endothelial cells can effectively decrease lectin-like oxidation of LDL receptor-1 and reactive oxygen species expression, thereby mitigating inflammation and oxidative stress responses and reducing the risk of CA-AKI. This evidence concerns the gene PCSK9 and cancer.